Geographic · Gross to Net Adjustments

United States — Gross to Net Adjustments

Bristol-Myers Squibb United States — Gross to Net Adjustments decreased by 54.3% to $4.80B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 41.5%, from $8.20B to $4.80B. Over 2 years (FY 2023 to FY 2025), United States — Gross to Net Adjustments shows an upward trend with a 18.9% CAGR.

Analysis

StatementSegment
First reportedQ1 2023
Last reportedQ1 2026Apr 30, 2026
Metric ID: bmy_segment_united_states_gross_to_net_adjustments

Historical Data

13 periods
 Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$5.50B$6.40B$7.30B$7.70B$6.90B$8.00B$8.90B$9.70B$8.20B$9.50B$9.80B$10.50B$4.80B
QoQ Change—+16.4%+14.1%+5.5%-10.4%+15.9%+11.3%+9.0%-15.5%+15.9%+3.2%+7.1%-54.3%
YoY Change————+25.5%+25.0%+21.9%+26.0%+18.8%+18.8%+10.1%+8.2%-41.5%
Range$4.80B – $10.50B
CAGR-4.4%
Avg YoY Growth+12.5%
Median YoY Growth+18.8%

Frequently Asked Questions

What is Bristol-Myers Squibb's united states — gross to net adjustments?
Bristol-Myers Squibb (BMY) reported united states — gross to net adjustments of $4.80B in Q1 2026.
How has Bristol-Myers Squibb's united states — gross to net adjustments changed year-over-year?
Bristol-Myers Squibb's united states — gross to net adjustments decreased by 41.5% year-over-year, from $8.20B to $4.80B.
What is the long-term trend for Bristol-Myers Squibb's united states — gross to net adjustments?
Over 2 years (2023 to 2025), Bristol-Myers Squibb's united states — gross to net adjustments has grown at a 18.9% compound annual growth rate (CAGR), from $26.90B to $38.00B.